Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation
EstadísticasView Usage Statistics
Full recordShow full item record
AuthorMartínez Sellés, Manuel; Bouza, Emilio; Díez Villanueva, Pablo; Valerio, Maricela; Fariñas Álvarez, María del Carmen; Muñoz García, Antonio J.; Ruiz Morales, Josefa; Gálvez Acebal, Juan; Antorrena, Isabel; Hera Galarza, Jesús María de la; Navas, Enrique; Muñoz, Patricia; GAMES study group
© Europa Digital & Publishing. "Reprinted from EuroIntervention Vol 11 number 10, Manuel Martínez-Sellés; Emilio Bouza; Pablo Díez-Villanueva et al., Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation, Pages 1180-7, Copyright 2016, with permission from Europa Digital & Publishing." The published paper from which material is reproduced must also be cited in the corresponding reference list.
Europa Digital & Publishing
Aims: To describe the characteristics of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). Methods and results: This study was performed using the GAMES database, a national prospective registry of consecutive patients with IE in 26 Spanish hospitals. Of the 739 cases of IE diagnosed during the study, 1.3% were post-TAVI IE, and these 10 cases, contributed by five centres, represented 1.1% of the 952 TAVIs performed. Mean age was 80 years. All valves were implanted transfemorally. IE appeared a median of 139 days after implantation. The mean age-adjusted Charlson comorbidity index was 5.45. Chronic kidney disease was frequent (five patients), as were atrial fibrillation (five patients), chronic obstructive pulmonary disease (four patients), and ischaemic heart disease (four patients). Six patients presented aortic valve involvement, and four only mitral valve involvement; the latter group had a higher percentage of prosthetic mitral valves (0% vs. 50%). Vegetations were found in seven cases, and four presented embolism. One patient underwent surgery. Five patients died during follow-up: two of these patients died during the admission in which the valve was implanted. Conclusions: IE is a rare but severe complication after TAVI which affects about 1% of patients and entails a relatively high mortality rate. IE occurred during the first year in nine of the 10 patients.